SCHEMBL7203233

SCHEMBL7203233

CCOC(=O)C1COc2ccc(C(C)=O)cc2O1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
KDM4E B2RXH2 2/20 0.47
ATM Q13315 1/20 0.46
POLB P06746 4/20 0.44
ALDH1A1 P00352 3/20 0.44
APEX1 P27695 1/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9255523 0.95 CYP4F2 (0.47) CYP4F2CYP4A11KDM4EATMPOLB
SCHEMBL11456480 0.86 ATM (0.44) CYP4F2CYP4A11KDM4EATMPOLB
SCHEMBL11456481 0.86 ATM (0.44) CYP4F2CYP4A11KDM4EATMPOLB
SCHEMBL11446958 0.85 NPC1 (0.50) CYP4F2CYP4A11KDM4EATMPOLB
SCHEMBL11493699 0.85 KDM4E (0.50) KDM4EATMPOLBALDH1A1APEX1
SCHEMBL1519271 0.85 CYP4F2 (0.50) CYP4F2CYP4A11KDM4EATMPOLB
SCHEMBL23420316 0.84 ALDH1A1 (0.48) CYP4F2CYP4A11KDM4EATMPOLB
SCHEMBL11477888 0.84 CYP1A2 (0.53) ALDH1A1SMN1; SMN2L3MBTL1GAALMNA
SCHEMBL7204613 0.83 CYP4F2 (0.46) CYP4F2CYP4A11ATMPOLBALDH1A1
SCHEMBL1519097 0.83 POLB (0.58) CYP4F2CYP4A11KDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
US-5439909-A 2-Substituted with amide or thioamide group; antioxidant for lipoproteins, antilipemic agents, anticholesterol agents ADIR ET COMPAGNIE (FR) 1995-08-08 US disclosed
US-5420132-A Antilipemic agents ADIR ET COMPAGNIE (FR) 1995-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 CYP4F2 389/4885CYP4A11 366/4885KDM4E 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.